The effects of chymase on matrix metalloproteinase-2 activation in neointimal hyperplasia after balloon injury in dogs

Hypertension Research

Volumn 30, Issue 1, 2007, Pages 77-83

  Kishi, Kanta ^a   Muramatsu, Michiko ^a   Jin, Denan ^a   Furubayashi, Keiichi ^a   Takai, Shinji ^a   Tamai, Hiroshi ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Matrix metalloproteinase; Neointimal formation; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; CHYMASE; GELATINASE A; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; SMOOTH MUSCLE FIBER;

ACETAMIDES; ANIMALS; BALLOON DILATATION; CAROTID ARTERIES; CELL MOVEMENT; CELLS, CULTURED; CHYMASES; DOGS; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME PRECURSORS; GELATINASES; HUMANS; HYPERPLASIA; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PYRIMIDINES; TUNICA INTIMA;

EID: 33847015563     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.77     Document Type: Article

References (32)

1. Serruys PW, Luijten HE, Beatt KJ, et al: Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-371.
2. McBride W, Lange RA, Hillis LD: Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med 1988; 318: 1734-1737.
3. Liu MW, Roubin GS, King SB 3rd: Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-1387.
4. Epstein SE, Speir E, Unger EF, Guzman RJ, Finkel T: The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol 1994; 23: 1278-1288.
5. Waeber B, Brunner HR: Cardiovascular hypertrophy: role of angiotensin II and bradykinin. J Cardiovasc Pharmacol 1996; 27: S36-S40.
6. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
7. MERCATOR Study Group: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992; 86: 100-110.
8. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
9. Miyazaki M, Wada T, Shiota N, Takai S: Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 1999; 13 (Suppl 1): S21-S25.
10. Takai S, Sakonjo H, Fukuda K, et al: A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N- 3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 2003; 304: 841-844.
11. Suzuki K, Lees M, Newlands GF, Nagase H, Woolley DE: Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J 1995; 305: 301-306.
12. 92 bonds of the catalytic domain. J Biol Chem 1997; 272: 25628-25635.
13. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G: A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280:9291-9296.
14. Legallicier B, Trugnan G, Murphy G, Lelongt B, Ronco P: Expression of the type IV collagenase system during mouse kidney development and tubule segmentation. J Am Soc Nephrol 2001; 12: 2358-2369.
15. Moses MA, Marikovsky M, Harper JW, et al: Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem 1996; 60: 379-386.
16. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-68.
17. Karelina TV, Goldberg GI, Eisen AZ: Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. J Invest Dermatol 1995; 105: 411-417.
18. Knox JB, Sukhova GK, Whittemore AD, Libby P: Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997; 95: 205-212.
19. Li Z, Li L, Zielke HR, Cheng L, et al: Increased expression of 72-kD type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-128.
20. George SJ, Johnson JL, Angelini GD, Jeremy JY: Short-term exposure to thapsigargin inhibits neointima formation in human saphenous vein. Arterioscler Thromb Vasc Biol 1997; 17: 2500-2506.
21. Bassiouny HS, Song RH, Hong XF, Singh A, Kocharyan H, Glagov S: Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation 1998; 98: 157-163.
22. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M: Characterization of chymase from human vascular tissues. Clin Chim Acta 1997; 265: 13-20.
23. Oleksyszyn J, Powers JC: Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry 1991; 30: 485-493.
24. Kirimura K, Takai S, Jin D, et al: Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 2005; 28: 457-464.
25. Descamps FJ, Martens E, Opdenakker G: Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest 2002; 82: 1607-1608.
26. Takai S, Kirimura K, Jin D, et al: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
27. Lange RA, Flores ED, Hillis LD: Restenosis after coronary balloon angioplasty. Annu Rev Med 1991; 42: 127-132.
28. Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW: Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation 1997; 96: 3555-3560.
29. Atkinson SJ, Crabbe T, Cowell S, et al: Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 1995; 270: 30479-30485.
30. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995; 270: 5331-5338.
31. Kanemitsu H, Takai S, Tsuneyoshi H, et al: Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 2006; 29: 57-64.
32. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST: Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-α. Am J Physiol Cell Physiol 2004; 286: C779-C784.